GSA Capital Partners LLP Buys Shares of 128,573 Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Key Points

• GSA Capital Partners LLP has acquired a new position in Ginkgo Bioworks Holdings, Inc., purchasing 128,573 shares valued at approximately $733,000.
• Institutional investors collectively own 78.63% of Ginkgo Bioworks, with notable stake increases from firms like Bank of America, which boosted its investment by 780.6% in the fourth quarter.
• The company reported a net loss of ($1.58) EPS in its last quarterly earnings, missing estimates by ($0.35), though its revenue of $48.32 million exceeded expectations.

GSA Capital Partners LLP bought a new position in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 128,573 shares of the company's stock, valued at approximately $733,000. GSA Capital Partners LLP owned approximately 0.22% of Ginkgo Bioworks at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Bank of America Corp DE increased its position in Ginkgo Bioworks by 780.6% during the fourth quarter. Bank of America Corp DE now owns 3,764,455 shares of the company's stock worth $36,967,000 after buying an additional 3,336,964 shares during the last quarter. Forbes J M & Co. LLP raised its holdings in shares of Ginkgo Bioworks by 56.0% in the 1st quarter. Forbes J M & Co. LLP now owns 1,094,564 shares of the company's stock worth $6,239,000 after purchasing an additional 392,832 shares during the period. Millennium Management LLC grew its stake in Ginkgo Bioworks by 357.4% in the 4th quarter. Millennium Management LLC now owns 670,065 shares of the company's stock valued at $6,580,000 after buying an additional 523,571 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Ginkgo Bioworks by 4.9% during the 4th quarter. Geode Capital Management LLC now owns 437,025 shares of the company's stock worth $4,294,000 after acquiring an additional 20,394 shares during the last quarter. Finally, Prescott Group Capital Management L.L.C. raised its stake in shares of Ginkgo Bioworks by 1.1% during the first quarter. Prescott Group Capital Management L.L.C. now owns 365,717 shares of the company's stock valued at $2,085,000 after acquiring an additional 3,967 shares during the last quarter. 78.63% of the stock is currently owned by institutional investors.

Ginkgo Bioworks Price Performance

NYSE DNA traded down $0.43 during mid-day trading on Wednesday, reaching $13.85. The stock had a trading volume of 765,373 shares, compared to its average volume of 1,520,596. Ginkgo Bioworks Holdings, Inc. has a 1 year low of $5.00 and a 1 year high of $16.85. The stock has a market cap of $810.64 million, a PE ratio of -1.51 and a beta of 1.50. The company has a fifty day moving average price of $10.33 and a 200 day moving average price of $9.40.

Ginkgo Bioworks (NYSE:DNA - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.35). The company had revenue of $48.32 million during the quarter, compared to analysts' expectations of $38.70 million. Ginkgo Bioworks had a negative return on equity of 52.35% and a negative net margin of 198.84%. As a group, equities research analysts expect that Ginkgo Bioworks Holdings, Inc. will post -10.02 earnings per share for the current year.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.